Table 1_Interleukin-26 expression in tuberculosis disease and its regulatory effect in macrophage polarization and intracellular elimination of Mycobacterium tuberculosis.docx by Kaisong Huang (5412626)

“…In this study, we observed significantly elevated IL-26 mRNA expression in peripheral blood mononuclear cells of active-TB patients compared to healthy individuals. …”

DataSheet1_An observational study of lower limb muscle imbalance assessment and gait analysis of badminton players.docx by Ping Huang (30439)

“…Lower limb muscle imbalance can cause gait abnormalities and increase the risk of muscle injury or decreased performance in significantly asymmetrical situations. …”

Data Sheet 1_Continuous cropping of Patchouli alters soil physiochemical properties and rhizosphere microecology revealed by metagenomic sequencing.docx by Guangtao Gu (20548532)

“…Metagenomic sequencing results showed that CC significantly changed the diversity and composition of rhizosphere microbial communities. …”

Table 1_Continuous cropping of Patchouli alters soil physiochemical properties and rhizosphere microecology revealed by metagenomic sequencing.xlsx by Guangtao Gu (20548532)

“…Metagenomic sequencing results showed that CC significantly changed the diversity and composition of rhizosphere microbial communities. …”

Data Sheet 1_Correlation between cortical morphology and synaptic-associated proteins levels in poststroke aphasia: a pilot study.docx by Yun Cao (111731)

Table 1_Effect of a mindfulness-based cognitive behavior therapy intervention on occupational burnout among school teachers.docx by Netra Raj Paudel (20610806)

“…</p>Results<p>The mean level of EE decreased during the post-test for both treatment (mean change -0.93, 95% CI: -2.56 to 0.70) and control (-1.71, 95% CI: -3.24 to -0.18) arms. …”

Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The primary outcome was change in glomerular filtration rate (GFR) and chronic kidney disease (CKD) stage. …”

Effects of cell-type specific h- and m-adaptation gains on SLE rates. by Scott Rich (9873638)

“…With few exceptions changes in and exhibit a significantly different SLE rate from the default values. …”

Table 1_GLP1 receptor agonists and SGLT2 inhibitors for the prevention or delay of type 2 diabetes mellitus onset: a systematic review and meta-analysis.docx by Farah Ghobar (22480732)

“…Finally, no significant change in fasting insulin levels was noticed with an overall SMD of -1.74 (95% CI: [-6.84, 3.37]), which was also not statistically significant (p-value: 0.55). …”